Shuttle Pharma doses first patient at UVA Cancer Center in Phase 2 glioblastoma trial of Ropidoxuridine

Shuttle Pharmaceuticals Holdings, Inc.

First patient enrolled and dosed at UVA Cancer Center; second site after Miami Cancer Institute.
Phase 2 trial: 40 patients randomized to 1,200 or 960 mg/day to determine optimal dose, then add 14 more.
Trial targets IDH wild-type, methylation negative glioblastoma; median survival <12 months with only radiation.
Ropidoxuridine has FDA Orphan Drug Designation for glioblastoma.
Six centers conducting trial: UVA, Georgetown, John Theurer, Allegheny Health, Miami Cancer Institute.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.